Avastin sBLA Clears Advisory Committee, Faces Quality of Life Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
Accelerated approval for glioblastoma multiforme can be based on objective response rate, panel tells FDA.
You may also be interested in...
Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint
FDA questions whether imaging improvements in patients with glioblastoma metaforme are sufficient to denote clinical change.
Schering-Plough's Temodar Clears FDA For First-Line Use In Glioblastoma
Approval of temozolomide was based on a Phase III trial that demonstrated a statistically significant survival benefit in combination with radiotherapy versus radiotherapy alone. Temodar also received full approval for its original indication of anaplastic astrocytoma.
Gliadel Marketing For Newly-Diagnosed Glioma Will Highlight Survival Benefit
Guilford's marketing of Gliadel for use in patients undergoing surgery for newly-diagnosed malignant glioma will highlight the survival benefit, the company said after receiving the supplemental indication